⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9573401 | 0.73 | — | — | |
| SCHEMBL3578716 | 0.73 | — | — | |
| Acetic Acid SCHEMBL6509778 | 0.73 | FFAR3 (0.39) | — | |
| SCHEMBL3266002 | 0.71 | — | — | |
| SCHEMBL2762826 | 0.71 | — | — | |
| SCHEMBL9363649 | 0.71 | — | — | |
| SCHEMBL5785619 | 0.71 | — | — | |
| SCHEMBL9363647 | 0.71 | — | — | |
| SCHEMBL594962 | 0.69 | — | — | |
| SCHEMBL1646018 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 374 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4682128-B2 | — | — | 2011-05-11 | — | — | JP | claimed |
| EP-1633717-B1 | P2X7 RECEPTOR ANTAGONISTS AND THEIR USE | ASTRAZENECA AB (SE) | 2009-10-28 | — | — | EP | claimed |
| US-20090143354-A1 | P2X7 Receptor Antagonists and Their Use | ASTRAZENECA AB (SE) | 2009-06-04 | — | — | US | claimed |
| US-20080182874-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-07-31 | — | — | US | claimed |
| CN-101111488-A | Novel compounds | ASTRAZENECA AB (SE) | 2008-01-23 | — | — | CN | claimed |
| EP-1824838-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2007-08-29 | — | — | EP | claimed |
| US-20060293337-A1 | P2x7 receptor antagonists and their use | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | US | claimed |
| CN-1832925-A | New p2x7 receptor avtagonists and their use | ASTRAZENECA AB (SE) | 2006-09-13 | — | — | CN | claimed |
| WO-2006059945-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2006-06-08 | — | — | WO | claimed |
| EP-1633717-A1 | NEW P2X7 RECEPTOR ANTAGONISTS AND THEIR USE | AstraZeneca AB (SE) | 2006-03-15 | — | — | EP | claimed |
| WO-2004106305-A1 | NEW P2X7 RECEPTOR ANTAGONISTS AND THEIR USE | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | WO | claimed |
| EP-0592676-B1 | IMINOSULFONYLUREA DERIVATIVE AND HERBICIDE | NISSAN CHEMICAL IND LTD (JP) | 1998-09-30 | — | — | EP | claimed |
| EP-0596109-B1 | SULFAMIDOSULFONAMIDE DERIVATIVES AND HERBICIDES | NISSAN CHEMICAL IND LTD (JP) | 1996-12-18 | — | — | EP | claimed |
| US-4663475-A | Ethylenically unsaturated N-(halosulfonyl) carbamyl monomers | THE DOW CHEMICAL COMPANY (US) | 1987-05-05 | — | — | US | claimed |
| US-12516049-B2 | Sulfonylurea ring substituted monocyclic β-lactam antibiotics | SUZHOU ERYE PHARMACEUTICAL CO., LTD (CN) | 2026-01-06 | — | — | US | disclosed |
| WO-2024127350-A1 | 2,6,9-TRISUBSTITUTED PURINES | ASTRAZENECA AB (SE) | 2024-06-20 | — | — | WO | disclosed |
| US-12012397-B2 | Sulphonyl urea derivatives as NLRP3 inflammasome modulators | NodThera Limited (GB) | 2024-06-18 | — | — | US | disclosed |
| US-4436912-A | 7-[2-(2-Aminooxazol-4-yl)-2-(oximino)acetamido cephalosporin antibiotics and intermediates therefor | ELI LILLY AND COMPANY (US) | 1984-03-13 | — | — | US | disclosed |
| US-4430499-A | 7-[2-(2-Aminooxazol-4-yl)-2-(oximino)acetamido]cephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1984-02-07 | — | — | US | disclosed |
| US-4278671-A | ANTIBIOTICS, BACTERICIDES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1981-07-14 | — | — | US | disclosed |